2022
Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Maaten J, Damman K. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation 2022, 145: 693-712. PMID: 35226558, PMCID: PMC9074837, DOI: 10.1161/circulationaha.121.052792.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsDisease-Free SurvivalEvidence-Based MedicineHeart FailureHumansRandomized Controlled Trials as TopicRenal Insufficiency, ChronicSurvival RateConceptsChronic kidney diseasePresence of CKDSevere chronic kidney diseaseHeart failure hospitalizationReduced ejection fractionHFrEF therapyHeart failureFailure hospitalizationEjection fractionMedical therapyKidney diseaseDrug classesSodium-glucose cotransporter 2 inhibitorsEvidence-based medical therapyGlucose cotransporter 2 inhibitorsStrong independent risk factorEnd pointCKD stage 3bPoor cardiovascular outcomesCKD stage 5Combined end pointCotransporter 2 inhibitorsIndependent risk factorSevere heart failureGlomerular filtration rate
2019
Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
Testani JM, Inzucchi SE, Voors AA. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time? Circulation 2019, 139: 2383-2385. PMID: 31107618, DOI: 10.1161/circulationaha.119.038854.Commentaries, Editorials and LettersBiomarkersBlood GlucoseDiabetes Mellitus, Type 2Disease ProgressionEvidence-Based MedicineGlucagon-Like Peptide-1 ReceptorHeart FailureHospitalizationHumansIncretinsProtective FactorsRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSodium-Glucose Transporter 2 InhibitorsTreatment Outcome